Intake of Ultra-processed Foods Is Associated with an Increased Risk of Crohn's Disease: A Cross-sectional and Prospective Analysis of 187 154 Participants in the UK Biobank.
Inflammatory bowel diseases
ultra-processed food
utrition
Journal
Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676
Informations de publication
Date de publication:
19 Apr 2023
19 Apr 2023
Historique:
medline:
21
4
2023
pubmed:
29
10
2022
entrez:
28
10
2022
Statut:
ppublish
Résumé
Ultra-processed food [UPF] consumption has been linked to globally increasing incidence and prevalence of chronic diseases, including inflammatory bowel diseases [IBD]. We aimed to investigate the association between UPF consumption and IBD incidence, prevalence, and IBD-relevant outcomes. We performed a cross-sectional and prospective cohort study in 187 854 individuals included in the national UK Biobank, using 24-h dietary recall questionnaires. Multivariable logistic regression and Cox proportional hazard regression were used to examine the association between UPFs and the prevalence and incidence risk of IBD, respectively. A total of 185 849 participants with a mean age of 56.2 were included, with a mean follow-up of 9.84 years. During follow-up, 841 developed IBD (251 Crohn's disease [CD], and 590 ulcerative colitis [UC]). UPF intake in IBD patients was significantly higher: CD: odds ratio [OR] 1.94 (95% confidence interval [CI]: 1.52, 2.49, p <0.001); UC: OR 1.39 [95% CI: 1.17, 1.65, p <0.001]. Compared with low consumption, higher UPF consumption was significantly associated with incident CD: hazard ration [HR] 2.00 [95% CI: 1.32, 3.03, p = 0.001], but not UC. We also found a significant association between UPF intake and need of IBD-related surgery: HR 4.06 [95% CI: 1.52, 10.86, p = 0.005]. Higher intake of UPFs was associated with higher incidence of CD, but not UC. In individuals with a pre-existing diagnosis of IBD, consumption of UPFs was significantly higher compared with controls, and was associated with an increased need for IBD-related surgery. Further studies are needed to address the impact of UPF intake on disease pathogenesis and outcomes.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Ultra-processed food [UPF] consumption has been linked to globally increasing incidence and prevalence of chronic diseases, including inflammatory bowel diseases [IBD]. We aimed to investigate the association between UPF consumption and IBD incidence, prevalence, and IBD-relevant outcomes.
METHODS
METHODS
We performed a cross-sectional and prospective cohort study in 187 854 individuals included in the national UK Biobank, using 24-h dietary recall questionnaires. Multivariable logistic regression and Cox proportional hazard regression were used to examine the association between UPFs and the prevalence and incidence risk of IBD, respectively.
RESULTS
RESULTS
A total of 185 849 participants with a mean age of 56.2 were included, with a mean follow-up of 9.84 years. During follow-up, 841 developed IBD (251 Crohn's disease [CD], and 590 ulcerative colitis [UC]). UPF intake in IBD patients was significantly higher: CD: odds ratio [OR] 1.94 (95% confidence interval [CI]: 1.52, 2.49, p <0.001); UC: OR 1.39 [95% CI: 1.17, 1.65, p <0.001]. Compared with low consumption, higher UPF consumption was significantly associated with incident CD: hazard ration [HR] 2.00 [95% CI: 1.32, 3.03, p = 0.001], but not UC. We also found a significant association between UPF intake and need of IBD-related surgery: HR 4.06 [95% CI: 1.52, 10.86, p = 0.005].
CONCLUSION
CONCLUSIONS
Higher intake of UPFs was associated with higher incidence of CD, but not UC. In individuals with a pre-existing diagnosis of IBD, consumption of UPFs was significantly higher compared with controls, and was associated with an increased need for IBD-related surgery. Further studies are needed to address the impact of UPF intake on disease pathogenesis and outcomes.
Identifiants
pubmed: 36305857
pii: 6779096
doi: 10.1093/ecco-jcc/jjac167
pmc: PMC10115229
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
535-552Subventions
Organisme : Cancer Research UK
ID : 22804
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.
Références
Public Health Nutr. 2019 Apr;22(5):936-941
pubmed: 30744710
Gastroenterology. 2021 Sep;161(3):837-852.e9
pubmed: 34052278
Gastroenterology. 2022 Mar;162(3):743-756
pubmed: 34774538
Inflamm Bowel Dis. 2022 Oct 3;28(10):1520-1526
pubmed: 34849925
Clin Nutr. 2021 Jul;40(7):4694-4701
pubmed: 34237696
Clin Nutr. 2021 May;40(5):3608-3614
pubmed: 33388205
Aliment Pharmacol Ther. 2007 Sep 15;26(6):795-806
pubmed: 17767463
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
Lancet. 1991 Sep 28;338(8770):771-4
pubmed: 1681159
Gut. 2021 Dec;70(12):2330-2336
pubmed: 33958435
Public Health Nutr. 2005 Oct;8(7A):1133-52
pubmed: 16277825
Gut. 1971 Feb;12(2):164-71
pubmed: 5548564
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30
pubmed: 31648971
Am J Gastroenterol. 2018 Apr;113(4):481-517
pubmed: 29610508
Am J Gastroenterol. 2011 Apr;106(4):563-73
pubmed: 21468064
Gastroenterology. 2018 Feb;154(3):518-528.e15
pubmed: 29102619
BMC Med. 2020 Apr 24;18(1):97
pubmed: 32326961
Am J Epidemiol. 2019 Oct 1;188(10):1858-1867
pubmed: 31318012
F1000Res. 2020 Jan 28;9:
pubmed: 32047622
Gastroenterology. 2016 Dec;151(6):e1-e5
pubmed: 27810482
Nat Genet. 2015 Sep;47(9):979-986
pubmed: 26192919
Curr Obes Rep. 2022 Sep;11(3):80-92
pubmed: 34677812
Aliment Pharmacol Ther. 2020 May;51(10):935-947
pubmed: 32249975
Clin Gastroenterol Hepatol. 2022 Jun;20(6):e1323-e1337
pubmed: 34461300
J Crohns Colitis. 2021 Jun 22;15(6):1068-1079
pubmed: 33336247
J Nutr Sci. 2018 Feb 1;7:e6
pubmed: 29430297
J Acad Nutr Diet. 2022 Aug;122(8):1488-1498.e1
pubmed: 34999242
Scand J Gastroenterol. 2020 Apr;55(4):430-435
pubmed: 32370571
Eur J Nutr. 2021 Oct;60(7):4019-4030
pubmed: 33956230
Aliment Pharmacol Ther. 2019 Jan;49(1):41-50
pubmed: 30484878
Inflamm Bowel Dis. 2021 Jan 1;27(1):65-73
pubmed: 32055825
J Pharm Pharmacol. 2000 Feb;52(2):157-62
pubmed: 10714945
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Gastroenterology. 1994 Jul;107(1):3-11
pubmed: 8020674
Nature. 2015 Mar 5;519(7541):92-6
pubmed: 25731162
BMJ. 2021 Jul 14;374:n1554
pubmed: 34261638
Aliment Pharmacol Ther. 2022 Sep;56(6):1018-1029
pubmed: 35848057
BMJ Open. 2019 Oct 28;9(10):e027546
pubmed: 31662351
J Clin Epidemiol. 2004 Dec;57(12):1288-94
pubmed: 15617955
Cell Metab. 2021 Jul 6;33(7):1358-1371.e5
pubmed: 33989521